ArQule Announces Departure of Board Member.WOBURN, Mass. -- ArQule, Inc. (Nasdaq: ARQL) today announced the resignation of Tuan Ha-Ngoc, a director of the company, effective November 17, 2006. Mr. Ha-Ngoc is president and chief executive officer of AVEO Pharmaceuticals Inc. Because both ArQule and AVEO are engaged in oncology-focused drug discovery and development, Mr. Ha-Ngoc decided that it was an appropriate time for him to step down from the board of ArQule. "Tuan Ha-Ngoc's distinguished tenure on the board of ArQule has coincided with the company's transition to a clinical-stage research and development-based company from a chemical services business," said Dr. Stephen A. Hill, president and chief executive officer of ArQule. "He leaves the board of ArQule with my sincere thanks and with the best wishes of the entire board and management of our company." About ArQule ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are designed to affect key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms. The first of these, Activated Checkpoint (programming) checkpoint - Saving the current state of a program and its data, including intermediate results, to disk or other non-volatile storage, so that if interrupted the program could be restarted at the point at which the last checkpoint occurred. Therapy(SM) (ACT), is designed to kill cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer selectively while sparing normal cells through direct activation of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F E2F E-Mail to Fax 1 pathway, is partnered with Roche. ArQule's second cancer platform, Cancer Survival Protein modulation, has generated a clinical-stage product designed to inhibit a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. and metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases 1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to . For more information, please visit www.arqule.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion